NEW YORK, Oct. 29 – Atto BioScience, a Rockville, Md.-based biotech company,  has raised $3 million in its first round of private equity financing, the company said on Monday.

Emerging Technology Partners led the financing round.

The capital will help Atto to finish the development and commercialization of its first high-throughput single-cell-imaging system. This system, scheduled to launch later this year, was developed in collaboration with a major US pharmaceutical company, Atto said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.